Additional file 2 of Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation

Supplementary Material 2. Table S1. Details of the metabolites considered. Table S2. Full MR results testing for the effect of metabolites on cardiac outcomes. Table S3. Number of metabolites per class associated with cardiac outcomes. Table S4. Enrichment of significant metabolite classes per cardiac outcome. Table S5. Number of overlapping prioritised proteins per outcome. Table S6. Overview and characteristics of not yet druggable prioritised proteins and metabolites associated with atrial fibrillation, heart failure, dilated cardiomyopathy, or non-ischemic cardiomyopathy. Table S7. Final results of all MRs per prioritised protein. Table S8. HPA RNA over-expression in heart. Table S9. Druggability results of the prioritised proteins. Table S10. Frequency of indication and side-effects. Table S11. Reactome pathway enrichment. Table S12. Replicates of the proteins associated with cardiac outcomes. Table S13. Replicates of the proteins associated with metabolites.